JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Corvus Pharmaceuticals Inc

Suletud

7.16 -0.28

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.01

Max

7.35

Põhinäitajad

By Trading Economics

Sissetulek

-23M

-8M

Kasumimarginaal

-13,764.773

Töötajad

31

EBITDA

-360K

-10M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+94.99% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. nov 2025

Turustatistika

By TradingEconomics

Turukapital

224M

557M

Eelmine avamishind

7.44

Eelmine sulgemishind

7.16

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. okt 2025, 20:49 UTC

Tulu

Correction to Thermo Fisher Article on Oct. 22

23. okt 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23. okt 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. okt 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23. okt 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23. okt 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23. okt 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23. okt 2025, 22:49 UTC

Omandamised, ülevõtmised, äriostud

How Trump Sparked a New Era of State Capitalism -2-

23. okt 2025, 22:49 UTC

Omandamised, ülevõtmised, äriostud

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23. okt 2025, 22:17 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23. okt 2025, 21:41 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23. okt 2025, 21:05 UTC

Tulu

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23. okt 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

23. okt 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

23. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. okt 2025, 20:35 UTC

Tulu

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23. okt 2025, 20:28 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23. okt 2025, 20:15 UTC

Market Talk
Tulu

Global Commodities Roundup: Market Talk

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q Adj EPS $1.71

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q Sales $5.52B

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q EPS $1.67

23. okt 2025, 20:09 UTC

Tulu

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23. okt 2025, 20:07 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

23. okt 2025, 20:07 UTC

Market Talk
Tulu

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23. okt 2025, 20:07 UTC

Tulu

Blackstone Looks to IPOs for Investment Exits -- Update

23. okt 2025, 20:05 UTC

Tulu

Intel 3Q Gross Margin 38.2% >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23. okt 2025, 20:04 UTC

Tulu

Intel: 4Q Guidance Excludes Altera >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel Sees 4Q Adj EPS 8c >INTC

Võrdlus sarnastega

Hinnamuutus

Corvus Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

94.99% tõus

12 kuu keskmine prognoos

Keskmine 14 USD  94.99%

Kõrge 16 USD

Madal 11 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Corvus Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.165 / 3.5827Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat